Mamotest is Latin America's first tele-mammography network: mammography images taken at rural screening centers are read by urban specialists with AI support, and results are returned within 24 hours. Guillermo Pepe founded it in 2013, expanding from Argentina into Mexico and Spain, with talks progressing with Brazil and others. Its origin was hearing from his physician father that 'if found earlier, 98% of patients could be saved.' In Latin America, specialists and equipment are concentrated in cities; 80% of women over 40 cannot get a mammogram, and the breast-cancer survival rate (27%) is far below the U.S. (99%). Mamotest lets patients book via WhatsApp, and health navigators accompany them after diagnosis with information and psychological support. The company reports having screened 650,000 people cumulatively and detected 87% of cancer-positive cases at a treatable early stage. It says it can save up to $15M a year in public health costs. It holds B Corp certification, with investment from J&J Impact Ventures, Merck (MSD) and the Philips Foundation.
●●○ medium
There is no confirmed −; independently verified + decide the position (B). No unreachable strike-through.= non-additive meter
Mamotest: Catching breast cancer early through remote diagnosis. The letter is B; certainty is medium. Unconfirmed concerns are placed under “Watching.” (As of 2026-Q2; estimate based on public information.)
Main narrative
One person’s story (N1)
+ before → after
The father of founder Guillermo Pepe, a physician, used to say that by the time he found a patient's breast cancer it was always too far advanced—'maybe they could live a little longer, that was the best I could do.' When Pepe asked 'what can be done,' his father answered, 'if we could diagnose earlier, 98% of patients could be saved.' Those words became the starting point of Mamotest, delivering early detection through remote diagnosis.
Source nature: Impact Ventures by J&J Foundation / P2 Independent media / first-party disclosure (J&J Foundation). Positive effects are not used to offset negatives.
Positive / negative effects
+ effects
- As Latin America's first tele-mammography network, Mamotest has specialists read—with AI support—images taken at rural screening centers, returning results within 24 hours. It reports having screened 650,000 people cumulatively and detected 87% of cancer-positive cases at a treatable early stage. It says it can save up to $15M a year in public health costs, and beyond B Corp certification it has investment from Johnson & Johnson, Merck (MSD) and the Philips Foundation.P1 Independent evaluation (B Corp / J&J / Merck / Philips) / ImpactAlpha / LAVCA
− effects (confirmed)
- No confirmed −.
- I
- n
- d
- e
- p
- e
- n
- d
- e
- n
- t
- v
- e
- r
- i
- f
- i
- c
- a
- t
- i
- o
- n
- o
- f
- s
- c
- r
- e
- e
- n
- i
- n
- g
- c
- o
- u
- n
- t
- s
- ,
- e
- a
- r
- l
- y
- -
- d
- e
- t
- e
- c
- t
- i
- o
- n
- r
- a
- t
- e
- a
- n
- d
- m
- o
- r
- t
- a
- l
- i
- t
- y
- r
- e
- d
- u
- c
- t
- i
- o
- n
- (
- m
- a
- i
- n
- l
- y
- s
- e
- l
- f
- -
- r
- e
- p
- o
- r
- t
- e
- d
- )
- .
- A
- c
- c
- u
- r
- a
- c
- y
- a
- n
- d
- f
- a
- i
- r
- n
- e
- s
- s
- o
- f
- A
- I
- r
- e
- a
- d
- i
- n
- g
- .
- Expansion into Brazil and elsewhere; multi-modality of the AI-reading platform (BolderAi); expanding the screening network through public-private partnerships.
A second look
The core plus is early breast-cancer detection and fairer healthcare access for women who are hard to reach (People), corroborated by B Corp and by J&J/Merck/Philips. On the other hand, screening counts and early-detection rates are mainly self-reported; independent verification of the ultimate outcome indicator—mortality reduction—is still to come. The accuracy and fairness of AI reading are also subjects of ongoing verification.
Sources
How to read this assessment
- Reachable upper bound (ceiling): a confirmed − sets the ceiling, and independently verified + decide the position within it. + do not cancel out −.
- The weight of evidence is not symmetric: only confirmed − are counted; the volume of disputes or allegations goes under “Watching.” + are counted from independent evidence, while an organization’s own PR is treated as “reference.”
- Size is not value: scale is not used in the assessment. Matters that stay within money or competition—investors, shareholders, sanctions, trade secrets—are also excluded.
- The letter (assessment) and certainty (how reliable the information is) are separate axes.
This is a translation; the Japanese version is authoritative. The assessments here are generated automatically by AI based on published criteria. The operator does not alter individual results. Because they are AI-generated they may contain errors, and they are opinion and commentary, not statements of fact. Where evidence is insufficient, the entry is marked “On hold.” Requests for correction are accepted via the form.
Terms: Narrative Value = an assessment (A–G) of the distance between the story an organization tells and its reality / Ceiling meter = a visualization of the reachable upper bound / Watching = unconfirmed matters not counted / Protected stakeholders = people, animals, nature, and future generations. | Generated by: AI | As of: 2026-Q2 | Back to top